Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 241 to 255 of 476 results for learning disabilities

  1. Rehabilitation after traumatic injury (NG211)

    This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.

  2. Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

    Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.

  3. Tofacitinib for treating active ankylosing spondylitis (TA920)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active ankylosing spondylitis.

  4. Self-expanding implant insertion into the intersphincteric space for faecal incontinence (HTG564)

    Evidence-based recommendations on self-expanding implant insertion into the intersphincteric space for faecal incontinence. This involves inserting implants that expand and press together, forming a ring that creates an artificial sphincter.

  5. Joint replacement (primary): hip, knee and shoulder (QS206)

    This quality standard covers care for adults before, during and after primary elective hip, knee or shoulder joint replacement. It describes high-quality care in priority areas for improvement. It does not cover joint replacement as treatment for primary or secondary cancer affecting the bones.

  6. Alcohol interventions in secondary and further education (NG135)

    This guideline covers interventions in secondary and further education to prevent and reduce alcohol use among children and young people aged 11 up to and including 18. It also covers people aged 11 to 25 with special educational needs or disabilities in full-time education. It will also be relevant to children aged 11 in year 6 of primary school.

  7. Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.

  8. Urinary tract infections in adults (QS90)

    This quality standard covers diagnosing and managing urinary tract infections in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

  9. Care of dying adults in the last days of life (NG31)

    This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life. It aims to improve end of life care for people in their last days of life by communicating respectfully and involving them, and the people important to them, in decisions and by maintaining their comfort and dignity. The guideline covers how to manage common symptoms without causing unacceptable side effects and maintain hydration in the last days of life.

  10. Fetoscopic prenatal repair for open neural tube defects in the fetus (HTG536)

    Evidence-based recommendations on fetoscopic prenatal repair of open neural tube defects in the fetus. This involves keyhole surgery through the woman’s abdomen to close the gap in the baby’s spine.

  11. Depression in adults (QS8)

    This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.

  12. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

  13. Community engagement: improving health and wellbeing and reducing health inequalities (NG44)

    This guideline covers community engagement approaches to reduce health inequalities, ensure health and wellbeing initiatives are effective and help local authorities and health bodies meet their statutory obligations.

  14. Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)

    Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults.